Description
This program is supported by an independent education grant from Pfizer Global Medical Grants. This online education program has been designed for healthcare professionals globally.
In this virtual 45-minute Grand Rounds session, leading expert Rupert Bartsch, MD explores personalized maintenance strategies and the integration of endocrine therapy in first-line HER2-positive metastatic breast cancer. Dr. Bartsch will review the evolution of de-escalation trials post-CLEOPATRA, outline evidence-based timing for transitioning off cytotoxic induction, and demonstrate how to layer endocrine agents (± CDK4/6 inhibitors) to optimize disease control and quality of life.
Accreditation: 0.75 AMA PRA Category 1 Credits™
Session Highlights
- Bridge induction to maintenance: Trace the shift from dual-HER2 blockade plus taxane to contemporary de-escalation approaches and define clinical markers for safely shortening chemotherapy.
- Endocrine selection in practice: Review ER–HER2 crosstalk and key PERTAIN and PATINA data to select and sequence aromatase inhibitors, fulvestrant, and CDK4/6 inhibitors.
- Case-based decision making: Apply real-world case vignettes to tailor maintenance regimens based on tumor biology, prior therapy exposure, and patient preferences.
Who Should Watch
- Medical Oncologists
- Nurse Practitioners
- Physician Assistants
- Oncology Nurses
- Oncology Fellows
- Pharmacists
- Internal Medicine Physicians with Oncology Focus
- Other HCPs occupied with MBC care
Presented by
Rupert Bartsch, MD – Professor and Chair, Division of Breast Oncology, Comprehensive Cancer Center Vienna; Principal Investigator, European HER2+ MBC Consortium. Dr. Bartsch’s clinical research has shaped maintenance de-escalation paradigms and optimized endocrine layering strategies in HER2-positive metastatic disease.
Continuing Education Information
Commercial support: This activity received monetary support through an independent education grant from Pfizer
This continuing education activity will be provided by AffinityCE and MedAll. Physicians will be eligible for AMA PRA Category 1 Credit™. A statement of participation is available for other healthcare professionals.
Disclosures
Dr Rupert Bartsch has disclosed financial relationships with the following ineligible companies within the past 24 months: Amgen, AstraZeneca, Bristol Myers Squibb (BMS), Daiichi Sankyo, Eisai, Eli Lilly, Grünenthal, MSD, Novartis, Roche Pharmaceuticals, and Gilead Sciences. These relationships include advisory roles, lecture honoraria, research support, and travel support.
These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Bartsch intends to discuss non-FDA uses of drug products and/or devices and their unlabelled indications and will disclose to the audience when this discussion takes place.
AffinityCE staff, MedAll staff, and all planners and reviewers have no relevant financial relationships with ineligible companies to disclose.
Activity Accreditation for Health Professions
This activity will be planned and implemented in accordance with the accreditation requirements and policies of both the Accreditation Council for Continuing Medical Education (ACCME) and the European Board for Accreditation of Continuing Education for Health Professionals (EBAC). Through joint providership with AffinityCE (ACCME-accredited) and MedAll (EBAC-accredited), continuing education credit will be provided for both live and enduring activities.
EBAC Compliance and Credit Conversion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of EBAC.
In compliance with EBAC guidelines, all speakers and chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website at https://edhub.ama-assn.org/pages/applications. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
The Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC.
How to Earn Your CME Credit
In order to obtain your CME credit and receive your certificate, please join the webinar and complete the assessment at the end. You will receive a link to your certificate automatically after completing the assessment.
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
---
ACCME Continuing Education Information
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose. All disclosures from faculty will be presented prior to commencing the event.
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.
Activity Accreditation for Health Professions
Physicians
This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity a maximum of 0.75 AMA PRA Category 1 Credits™.
Physician Assistants
This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity a maximum of 0.75 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity a maximum of 0.75 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses & Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Unapproved and/or off-label use disclosure
AffinityCE/MedAll requires CE faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Participation Costs
There is no cost to participate in this program.
Pharmacists
Pharmacists AffinityCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE).
CE Title: HER2+ Metastatic Breast Cancer Grand Rounds: Latest Advances - Individualizing First-Line Therapy in Metastatic HER2-positive Breast Cancer
Format: Live Portion
UAN: 0829-9999-25-155-L01-P
Activity Type: Knowledge-based
CEUs: 0.75
No cost to participate.
Participant CE records will be electronically communicated to CPE Monitor.
Pharmacist Learning Objectives
At the conclusion of this web conference, participants should be able to:
- Explain evolution and rationale for maintenance de-escalation in 1L HER2⁺ MBC:
- Understand the role of endocrine therapy ± CDK4/6 inhibitors in HE2R+/HR+ MBC 1L setting:
System Requirements
Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program
CME Inquiries
For all CME policy-related inquiries, please contact us at ce@affinityced.com.